Catalyst Bio shares bashed as neutralizing antibodies force investigators to freeze hemophilia cohort work
Shares of Catalyst Biosciences $CBIO were badly damaged in the wake of an alert that two patients in one cohort of their early-stage hemophilia drug study developed a neutralizing antibody after a course of therapy with their Factor IX (FIX) candidate CB 2679d/ISU304.
Investigators have now suspended treatment in cohort 6 and will stay on hold until they figure out what went wrong. The two patients were able to resume treatment with their prescribed IV FIX prophylaxis therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.